اخبار و اعلانات

 آمار

تعداد نشریات286
تعداد نشریات سازمان84
تعداد شماره‌ها3,016
تعداد مقالات33,722
تعداد مشاهده مقاله44,957,495
تعداد دریافت فایل اصل مقاله45,789,283
Zhylkaidar, Arman, Hadi, A. M. (1402). A Comparative Study of Antiretroviral (Lopinavir/Ritonavir) and Remdesivir Used in the Pandemic in Iraq on the Clinical Outcome in Patients with SARS-CoV-2. سامانه مدیریت نشریات علمی, 78(3), 935-941. doi: 10.22092/ari.2022.360354.2574
Arman Zhylkaidar; A. M Hadi. "A Comparative Study of Antiretroviral (Lopinavir/Ritonavir) and Remdesivir Used in the Pandemic in Iraq on the Clinical Outcome in Patients with SARS-CoV-2". سامانه مدیریت نشریات علمی, 78, 3, 1402, 935-941. doi: 10.22092/ari.2022.360354.2574
Zhylkaidar, Arman, Hadi, A. M. (1402). 'A Comparative Study of Antiretroviral (Lopinavir/Ritonavir) and Remdesivir Used in the Pandemic in Iraq on the Clinical Outcome in Patients with SARS-CoV-2', سامانه مدیریت نشریات علمی, 78(3), pp. 935-941. doi: 10.22092/ari.2022.360354.2574
Zhylkaidar, Arman, Hadi, A. M. A Comparative Study of Antiretroviral (Lopinavir/Ritonavir) and Remdesivir Used in the Pandemic in Iraq on the Clinical Outcome in Patients with SARS-CoV-2. سامانه مدیریت نشریات علمی, 1402; 78(3): 935-941. doi: 10.22092/ari.2022.360354.2574

A Comparative Study of Antiretroviral (Lopinavir/Ritonavir) and Remdesivir Used in the Pandemic in Iraq on the Clinical Outcome in Patients with SARS-CoV-2

Archives of Razi Institute
مقاله 19، دوره 78، شماره 3، مرداد و شهریور 2023، صفحه 935-941    اصل مقاله (371.96 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2022.360354.2574
نویسندگان
Arman Zhylkaidar* 1؛ A. M Hadi2
1NJSC Kazakh National Agrarian University, 8 Abay Ave., Almaty, 050010, the Republic of Kazakhstan
2College of Pharmacy, University of Basra, Basra, Iraq
چکیده
The SARS-CoV-2 virus, which emerged in December 2019, has infected millions worldwide and caused many deaths. Due to its high mortality rate, several studies assessed the effectiveness of different drugs against COVID-19, mainly in reducing the hospitalization rate among the elderly and compromised patients. Lopinavir-ritonavir combination and remdesivir were among the medications used to treat COVID-19. Due to considerable differences in the effectiveness and clinical outcomes of the two treatments, this study aimed to compare the clinical outcomes between COVID-19 patients treated with antiretrovirals (lopinavir-ritonavir) and remdesivir. A total of 33 patients on lopinavir-ritonavir and 35 on remdesivir were selected for this study. A retrospective comparative analysis was conducted based on demographic characteristics, hospital stay, laboratory parameters of C-reactive protein (CRP) and plasma blood oxygen saturation (SPO2), clinical treatment, and a clinical outcome assessment extracted from hospital archive data. Both treatments improved patient outcomes, yet there was a significant difference between lopinavir-ritonavir and remdesivir groups in platelet count, CRP, SPO2, and monocyte results, with remdesivir showing better clinical outcomes. No significant difference was reported in white blood cells, lymphopenia, and lactate dehydrogenase between the two treatments. It is still necessary to conduct further research to determine how effective the two treatments are in treating severe COVID-19 cases due to the limited number of available studies and the inconsistency in research methods and measurements.
کلیدواژه‌ها
Antiretroviral drugs؛ Coronavirus؛ COVID-19؛ Lopinavir-ritonavir؛ Remdesivir؛ SARS-CoV-2
سایر فایل های مرتبط با مقاله
مراجع
  1. Ahmad T, Khan M, Haroon, Musa TH, Nasir S, Hui J, et al. COVID-19: Zoonotic aspects. Travel Med Infect Dis. 2020;36:101607.
  2. Chang D, Chang X, He Y, Tan KJK. The determinants of COVID-19 morbidity and mortality across countries. Sci Rep. 2022;12(1):5888.
  3. Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health. 2020;25(3):278-80.
  4. Hameed RY, Nathir I, Abdulsahib WK, Almashhadani HA. Study the effect of biosynthesized gold nanoparticles on the enzymatic activity of alpha-Amylase. Res J Pharm. 2022;15(8):3459-65.
  5. Nabi G, Khan S. Risk of COVID-19 pneumonia in aquatic mammals. Environ Res. 2020;188:109732.
  6. Patel TK, Patel PB, Barvaliya M, Saurabh MK, Bhalla HL, Khosla PP. Efficacy and safety of lopinavir-ritonavir in COVID-19: A systematic review of randomized controlled trials. J Infect Public Health. 2021;14(6):740-8.
  7. NIH. Clinical Management of Adults Summary. COVID-19 Treatment Guidelines 2022 [Available from: https://www.covid19treatmentguidelines.nih.gov/management/clinical-management/clinical-management-summary/?utm_source=site&utm_medium=home&utm_campaign=highlights.
  8. Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, et al. Risk factors for severe and critically ill COVID-19 patients: A review. Allergy. 2021;76(2):428-55.
  9. SAl-Shaheeb H, Hashim K, Mohammed AK, Almashhadani HA, Al Fandi A. Assessment of lipid profile with HbA1c in type 2 diabetic Iraqi patients. Revis Bionatura 2022;7(3):29.
  10. Vetter P, Vu DL, L'Huillier AG, Schibler M, Kaiser L, Jacquerioz F. Clinical features of covid-19. BMJ. 2020;369:1470.
  11. Chan JF, Yuan S, Kok KH, To KK, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514-23.
  12. van Eijk LE, Binkhorst M, Bourgonje AR, Offringa AK, Mulder DJ, Bos EM, et al. COVID-19: immunopathology, pathophysiological mechanisms, and treatment options. J Pathol. 2021;254(4):307-31.
  1. Young BE, Ong SWX, Kalimuddin S, Low JG, Tan SY, Loh J, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020;323(15):1488-94.
  2. Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis. 2015;212(12):1904-13.
  3. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3.
  4. Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis. 2003;36(12):1585-92.
  5. Luo P, Zheng JL, Liu Y, Qiu L, Liu XL, Xue HY, et al. Effectiveness of early treatment of lopinavir-ritonavir in patients with severe COVID-19: a case series. Clin Med (Lond). 2021;21(1):e80-e3.
  6. IDSA. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. 2020.
  7. Kalantari S, Fard SR, Maleki D, Taher MT, Yassin Z, Alimohamadi Y, et al. Comparing the effectiveness of Atazanavir/Ritonavir/Dolutegravir/Hydroxychloroquine and Lopinavir/Ritonavir/Hydroxychloroquine treatment regimens in COVID-19 patients. J Med Virol. 2021;93(12):6557-65.
  8. Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020;382(19):1787-99.
  9. Castle RD, Williams MA, Bushell WC, Rindfleisch JA, Peterson CT, Marzolf J, et al. Implications for Systemic Approaches to COVID-19: Effect Sizes of Remdesivir, Tocilizumab, Melatonin, Vitamin D3, and Meditation. J Inflamm Res. 2021;14:4859-76.
  10. Sevilla-Castillo F, Roque-Reyes OJ, Romero-Lechuga F, Gomez-Nunez MF, Castillo-Lopez M, Medina-Santos D, et al. Both Chloroquine and Lopinavir/Ritonavir Are Ineffective for COVID-19 Treatment and Combined Worsen the Pathology: A Single-Center Experience with Severely Ill Patients. Biomed Res Int. 2021;2021:8821318.
23.          Baden LR, Rubin EJ. Covid-19 - The Search for Effective Therapy. N Engl J Med. 2020;382(19):1851-2. 

آمار
تعداد مشاهده مقاله: 2,046
تعداد دریافت فایل اصل مقاله: 2,669


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب